Loading
IARC estimates 2,777 new cancer cases and 1,100 cancer deaths in Luxembourg in 2024; the commonest new cancers are breast, prostate and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 5 trials with a site there, 2 institutions, 1 company and 2 people, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Luxembourg's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 493 | 83.7 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 424 | 65.9 | Prostate cancer |
| Trachea, bronchus and lung | 315 | 22.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 310 | 22.8 | Colorectal cancer |
| Melanoma of skin | 149 | 12.0 | Melanoma |
| Bladder | 117 | 8.1 | Bladder & urothelial cancer |
| Pancreas | 112 | 7.5 | Pancreatic ductal adenocarcinoma |
| Non-Hodgkin lymphoma | 90 | 6.6 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 71 | 4.6 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Liver and intrahepatic bile ducts | 63 | 4.6 | Hepatocellular carcinoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 242 | 16.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 129 | 8.1 | Colorectal cancer |
| Breast | 104 | 12.4 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Pancreas | 98 | 6.4 | Pancreatic ductal adenocarcinoma |
| Prostate | 71 | 8.3 | Prostate cancer |
| Liver and intrahepatic bile ducts | 53 | 3.6 | Hepatocellular carcinoma |
| Leukaemia | 41 | 2.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Stomach | 35 | 2.3 | Gastric & gastro-oesophageal junction cancer |
| Bladder | 34 | 1.9 | Bladder & urothelial cancer |
| Non-Hodgkin lymphoma | 30 | 1.7 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 1/2 | Active not recruiting | Stemline Therapeutics, Inc. | 83 | 2026-06-12 | |
ALTA-1L NCT02737501 | Phase 3 | Completed | Ariad Pharmaceuticals | 91 | 2021-08-20 |
PROFILE 1014 NCT01154140 | Phase 3 | Completed | Pfizer | 249 | 2017-11-06 |
EORTC 22033-26033 NCT00182819 | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 89 | 2016-10-12 |
EORTC 22991 NCT00021450 | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2016-09-02 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Luxembourg, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Luxembourg is open is on the registry page, under Contacts and Locations.
People whose main affiliation in OnCo is an institution or company in Luxembourg.
Luxembourg is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.
Luxembourg is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.